REG - GSK PLC - Statement: Zantac (ranitidine) litigation

GSKAnnouncement

28/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240828:nRSb8946Ba&default-theme=true

RNS Number : 8946B  GSK PLC  28 August 2024

Issued: 27 August 2024, London UK

 

Statement: Zantac (ranitidine) litigation - Delaware Supreme Court to review
Superior Court's Daubert decision

 

 

 

GSK plc (LSE/NYSE: GSK) welcomes today's decision by the Delaware Supreme
Court that it will review the Delaware Superior Court's decision allowing the
introduction of plaintiffs' expert evidence at trial. Interlocutory reviews
are granted in exceptional circumstances, and GSK is pleased that the Supreme
Court is of the view that such circumstances are present here.

 

The scientific consensus remains that there is no consistent or reliable
evidence that ranitidine increases the risk of any cancer. Since 2019, there
are 16 epidemiological studies looking at human data regarding the use of
ranitidine, including outcomes for more than 1 million patients using
ranitidine, supporting this consensus.

 

GSK is committed to vigorously defending itself and managing this litigation
in the best interests of the Company and its shareholders. The Delaware
litigation will progress in parallel with the Delaware Supreme Court review.
Alongside review by the Delaware Supreme Court, the Company will press
additional defenses in the litigation, including failure to provide proof of
use and proof of diagnosis requirements recently ordered by the Court.

 

Notes to Editors

* The Daubert standard, established in the U.S. Supreme Court case Daubert v.
Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993) provides criteria for
evaluating whether expert testimony is admissible under Federal Rule of
Evidence 702. Under Rule 702 and Daubert, an expert may offer testimony if he
or she is qualified by knowledge, education, training or experience in a given
area and the testimony offered is reliable, relevant and helpful to the jury.
In applying the Daubert standard, the Court acts as a gatekeeper, ensuring
that expert opinions meet certain standards for reliability and that
speculative or unreliable opinions are not presented to the jury.  In
Daubert, the Supreme Court identified four factors to guide assessment of an
expert's methodology: (1) whether the expert's methodology has been tested or
is capable of being tested; (2) whether the theory or technique used by the
expert has been subjected to peer review and publication; (3) whether there is
a known or potential error rate of the methodology; and (4) whether the
technique has been generally accepted in the relevant scientific community.
The Daubert standard is applicable to expert testimony in all federal cases.
Many states also have adopted standards identical to the federal Daubert
standard.

 

The term "Daubert Standard" comes from the United States Supreme Court case:
Daubert v Merrell Dow Pharmaceuticals Inc 509 US 579 (1993).

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Dan Smith          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q2 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STREANPXADDLEFA